Down 3.6% today, more than its industrial peers' 0.5%; no story names it yet.
Ahead of the market
Up 69% in a year while the S&P 500 rose 12%.
“Consolidated revenue increased 11% to a first quarter record $187 million, driven by Clinical revenue growth of 14%.”
NEO's Quality Score fell 2 points on Tue, Nov 10, to 8. It closed away from its high of the day (3 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| The company | Sales up 11% on the year |
| Latest filing | 8-K, Oct 28 |
TodayNo story names it yet.
NeoGenomics filed an 8-K reporting a change of CEO
NEO closed −13.7% the next session (Oct 6) on 2.3x normal volume.
Tue Dec 1: Piper Sandler 38th Annual…Investor conference · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 4 reports it closed +3.4% on average, higher 2 of 4 times.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
NEO is #145 of 457 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 145 |
Expected to report Tue Feb 16, after the close (in 98 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $209.3M, 11% more than a year ago; a loss of $0.06 a share, from $0.21.
“Increased clinical revenue by 13% to $195 million driven by NGS growth of 29%”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Client Direct Billing | $136M | $138M | $132M |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 28)
No outlook figures read from this release.
“At the same time, we expect to reduce complexity across our business through operational excellence initiatives designed to deliver accelerating growth and disciplined margin expansion over the long-term.”
From its results filing (SEC filing · Oct 28)
Sales grew 10% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 2.8% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 28, 2026 | -4.1% | -0.3% | -4.7% |
| Jul 28, 2026 | +15.4% | +14.0% | +21.6% |
| Apr 28, 2026 | +13.6% | -0.7% | -1.8% |
| Feb 17, 2026 | -7.7% | +0.5% | -12.4% |
Sales grew every year from 2018 to 2025, to $727M. It made a profit in three of the eight years.
RSI 48.6, MACD above signal, below its 50-day, above its 200-day. Not scored.
One insider sold $321K across 1 filing in the last 6 months. No open-market buys on record. The newest:
4 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: NEO is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
“Our competitors within the broader genomics profiling space include laboratory companies such as Quest Diagnostics, Laboratory Corporation of America and ARUP.”
NEO scores 8 today, which Breakaway calls Average. It is #145 of 457 in Industrials by Quality Score, with 4 of 14 chart checks firing. Up 69% in a year while the S&P 500 rose 12%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
NEO scores 8 today, which Breakaway calls Average (6 to 10). That is #145 of 457 in Industrials by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind NEO's 8.
One insider sold $321K across 1 filing in the last 6 months. No open-market buys on record. The newest is Greg D. Aunan, Chief Accounting Officer, who sold $321K on Aug 4.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.